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Abstract
Background: It is generally believed that exhaustive searches of bibliographic databases are
needed for systematic reviews of health care interventions. The CENTRAL database of controlled
trials (RCTs) has been built up by exhaustive searching. The CONSORT statement aims to
encourage better reporting, and hence indexing, of RCTs. Our aim was to assess whether
developments in the CENTRAL database, and the CONSORT statement, mean that a simplified
RCT search strategy for identifying RCTs now suffices for systematic reviews of health care
interventions.
Methods: RCTs used in the Cochrane reviews were identified. A brief RCT search strategy
(BRSS), consisting of a search of CENTRAL, and then for variants of the word random across all
fields (random$.af.) in MEDLINE and EMBASE, was devised and run. Any trials included in the meta-
analyses, but missed by the BRSS, were identified. The meta-analyses were then re-run, with and
without the missed RCTs, and the differences quantified. The proportion of trials with variants of
the word random in the title or abstract was calculated for each year. The number of RCTs
retrieved by searching with "random$.af." was compared to the highly sensitive search strategy
(HSSS).
Results: The BRSS had a sensitivity of 94%. It found all journal RCTs in 47 of the 57 reviews. The
missing RCTs made some significant differences to a small proportion of the total outcomes in only
five reviews, but no important differences in conclusions resulted. In the post-CONSORT years,
1997–2003, the percentage of RCTs with random in the title or abstract was 85%, a mean increase
of 17% compared to the seven years pre-CONSORT (95% CI, 8.3% to 25.9%). The search using
random$.af. reduced the MEDLINE retrieval by 84%, compared to the HSSS, thereby reducing the
workload of checking retrievals.
Conclusion: A brief RCT search strategy is now sufficient to locate RCTs for systematic reviews
in most cases. Exhaustive searching is no longer cost-effective, because in effect it has already been
done for CENTRAL.
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Background
Literature searching for systematic reviews of interven-
tions in health care has been largely based on finding all
randomized controlled trials (RCTs), as this study design
is considered the gold standard. However RCTs make up
only a very small proportion of all the articles included in
bibliographic databases, and so the problem for system-
atic reviewers has been to devise a search strategy which is
sensitive enough to find all the RCTs, but specific enough
not to bury them in a large number of other unwanted
retrievals needing to be manually excluded.
Two developments have facilitated searching for RCTs.
The first is CENTRAL (the Cochrane Central Register of
Controlled Trials), the world's most comprehensive data-
base consisting exclusively of controlled clinical trials. It
currently contains over 425,000 citations. The majority of
the trials in CENTRAL have been identified through sys-
tematic searches of MEDLINE and EMBASE. The first two
phases of a three phase highly sensitive search strategy
(HSSS) have been used to search MEDLINE [1]. CENTRAL
also includes citations to reports of controlled trials that
are not indexed in MEDLINE or EMBASE, derived through
searches of other bibliographic databases, and extensive
hand searching.
Because identification has relied solely on the titles and,
where available, the abstracts, some relevant trials may
not have been identified. Therefore, the Cochrane Hand-
book says "it may still be worthwhile for reviewers to search
MEDLINE using the Cochrane highly sensitive search strategy
and to obtain and check the full reports of possibly relevant cita-
tions" [2]. However, this strategy is complicated to run,
and may require time-consuming screening of abstracts,
and perhaps of full articles.
The second development is the CONSORT statement,
introduced in 1996 [3], and since revised [4]. CONSORT
comprises a 22 item checklist and a flow diagram to help
improve the quality of reports of RCTs, and has been
endorsed by prominent medical journals There is evi-
dence from a comparative before-and-after evaluation
that there has been an increase over time in the number of
CONSORT checklist items included in the reports of RCTs
[5].
Item 1 on the CONSORT checklist recommends that the
method in which participants were allocated to interven-
tions (e.g., "random allocation", "randomized" or "ran-
domly assigned") is described in the title and abstract.
This allows instant identification of RCTs, and should
help ensure that a study is appropriately indexed as an
RCT in bibliographic databases.
As the Cochrane Collaboration has already done exhaus-
tive work to ensure that CENTRAL is as complete as possi-
ble, we wanted to examine whether this eliminates the
need for individual reviewers to run the HSSS, and the
effectiveness of replacing this with a simplified search
strategy.
The aims were
1. To determine the effect on the results of Cochrane
reviews of using a brief RCT search strategy (BRSS).
2. To examine the change in use of variants of the word
random in the title or abstract of journal articles, pre- and
post-CONSORT.
Methods
All reviews new to the Cochrane Database of Systematic
Reviews in the Cochrane Library 2004 issue 2 were
selected. Those that stated that they were considering only
RCTs, and which found at least one RCT, were selected.
All trials included in each review were identified from the
section 'References to studies included in this review'.
Each trial was checked to determine whether it was
indexed in CENTRAL (on Cochrane Library 2004, issue
2), and then MEDLINE. If not in either of these databases,
EMBASE was checked.
The full bibliographic records of all trials that were in
either MEDLINE or EMBASE (using the OVID interface)
were examined to determine whether random$ was in any
field. (Random$.af. means a search of variants of random
in all fields, where $ is truncation symbol).
The full papers of any trials that were: 1) not in CENTRAL,
or 2) did not have random$ in any field in the biblio-
graphic record, were obtained and checked to see whether
they were actually RCTs. All non-English articles were
translated, apart from those in Japanese and Chinese, as
resources were not available.
The impact of omitting the RCTs not found with the BRSS
was quantified, using Review Manager 4.2.7. The forest
plots for the meta-analyses were reproduced, both with
and without data from the missing trials, and the results
compared to see if omission would make any important
difference. The differences could theoretically include;
a) There might be less, or no data left, for some outcomes.
b) There could be a different result; no benefit over com-
parator, or vice versa.
c) There could be the same result, but with a different
effect size.BMC Medical Research Methodology 2005, 5:23 http://www.biomedcentral.com/1471-2288/5/23
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d) There could be the same result and effect size, but with
a wider confidence interval, and possibly loss of statistical
significance.
In summary, the BRSS would involve: 1) searching CEN-
TRAL, and 2) supplementing that with a search of
MEDLINE and EMBASE, using a search of 'random$.af.' to
pick up trials not in CENTRAL.
Results
There were 78 new reviews, of which 57 met the inclusion
criteria. They cited a total of 920 trials; 79% (725) were
journal articles. The remaining 21% were from the grey lit-
erature, 80% of these being conference abstracts).
Twenty one reviews were excluded from our study; 14
because they did not find any RCTs that met their inclu-
sion criteria, and seven because they included other study
designs in addition to RCTs.
Determination of the proportion of journal articles found 
using the BRSS
It was found that 93.3% (677) of the 725 journal articles
included in the systematic reviews were in CENTRAL. It
was assumed that these were all RCTs, but this was not
checked due to the large numbers involved (and it was not
relevant to the aims of the study). This left 48 journal arti-
cles not indexed in CENTRAL.
The full texts of all 48 of these articles (apart from the four
in Japanese and five in Chinese) were translated and
checked. It was found that 40 were RCTs, and the remain-
ing eight used non-RCT study designs. (It was assumed
that the untranslated articles were RCTs). Eleven of the 40
RCTs were found by searching MEDLINE or EMBASE with
'random$.af'. Therefore, 29 (4%) of RCTs would not have
been found with the BRSS.
Details of the 29 RCTs not found by the BRSS
The 29 trials were distributed over 12 reviews. Ten were in
MEDLINE, 11 in EMBASE only. Twelve were non-English
language.
In two reviews [6,7], each with one missing trial, the data
used in the meta-analyses were available in two other
papers; both were in CENTRAL, and included in the
reviews. Zhang 1990 [8] was confirmed (by authors of the
review) to be the same trial as Chang 1996 [9]. The data
in the Stensrud trial [10] was also reported in another
paper by Stensrud [11].
Therefore, this leaves 27 missing journal articles, in 10
separate reviews that contain at least one trial with data
not found by the BRSS. Table 1 shows the detail of these
trials and the impact of excluding them from the reviews.
Only one review did not do a meta-analysis[12] The nine
remaining reviews did a total of 129 meta-analyses of var-
ious outcomes. In five out of the 10 reviews the missing
trials made no significant difference, in that there were no
clinically significant changes in effect size, nor any change
in whether results were statistically significant or not.
Hence, there was some difference in only five reviews.
The impact of the 'missing trials' being excluded from the 
reviews
Two consequences of missing data were found:
1) In three reviews [13-15], the missing trials were the
only ones providing data for seven (of a total 35) out-
comes, so no data were available for these seven out-
comes. In a fourth review [16], omission of a trial would
lose 92% of patients for two outcomes out of 28, but this
did not change the significance or direction of the result.
2) In three reviews [15-17], the meta-analyses lost statisti-
cal significance due to the wider confidence intervals, for
three of 74 outcomes, but one of these was not a clinical
outcome.
Comparison of retrieval of HSSS and random$.af. in 
MEDLINE
For the period 1966 to October, 2004, the HSSS search
strategy retrieved 2,505,742 records in MEDLINE, com-
pared to 'random$.af.', which retrieved 399,208 records.
Therefore, only 16% of the number of records were found
using 'random$.af.', compared to HSSS.
CONSORT and the change over time in the proportion of 
RCTs with random$ in title or abstract
Using the 725 journal articles in our sample, we compared
the frequency of random$ in the title or abstract between
pre-CONSORT (published up to 1996) and post-CON-
SORT trials (published from 1997 onwards). Figure 1
shows the change in the proportion of RCTs with 'ran-
dom$' in the title or abstract (with three year moving aver-
age trendline added).
In the post-CONSORT years, 1997–2003, the term
appeared in 85% of the titles or abstracts, compared to
68% in the seven years before CONSORT (1990–96);
mean difference was 17% (95% CI 8.3 to 25.9%; p =
0.001). If a longer pre-CONSORT period is used, 1980 to
1996, the proportion is similar at 62%.
Discussion
Using the BRSS, rather than the much more exhaustive
HSSS, to retrieve RCTs in journal articles for Cochrane
reviews, affected only a very small percentage of total out-
comes of a few reviews, and made no important difference
to the conclusions of these reviews. The most affectedBMC Medical Research Methodology 2005, 5:23 http://www.biomedcentral.com/1471-2288/5/23
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review had four of the five included trials published in
Chinese [14].
The CONSORT statement appears to be associated with a
significant increase in the frequency of random in the
titles and abstracts of journal articles. Whether this is
directly due to CONSORT, or whether CONSORT simply
accelerated a pre-existing trend, and raised the general
awareness amongst authors and editors for better report-
ing of RCTs, is uncertain. This improved description of
Table 1: Summary of impact of excluding trials not found with brief RCT search.
Topic No RCTs 
included
Details of RCTs not found 
with BRSS
Effect on review of excluding the RCTs not found
Lymphoedema of the 
limbs [20]
4 1. Kasseroller (1996) [21] Kasseroller study involved in 2 of 17 meta-analyses; exclusion makes no 
significant difference to outcome of either meta-analysis.
Ventricular 
pacemakers [22]
34 1. Davis (1985) [23] Davis study included in 1 of 12 meta-analyses; exclusion makes no 
significant difference.
Early intervention for 
psychosis [13]
7 1. Linszen (1998) trial comprised 5 
papers; 2 not found with brief 
search.
a) Linszen (1998a) [24]
b) Linszen (1998b) [25]
Linszen study included in 1 of 12 meta-analyses. Excluding Linszen would 
mean that there would be no data for this outcome.
Interventions for 
impetigo [15]
60 1. Arata (1989a) [26]
2. Arata (1989b) [27]
3. Bass (1997) [28]
4. Koranyi (1976) [29]
5. Moraes Barbosa (1986) [30]
6. Park (1993) [31]
7. Pruksachat. (1993) [32]
8. Sutton (1992) [33]
9. Tamayo (1991) [34]
The 9 trials were included in 8 of the 19 meta-analyses in this review.
Outcome 1: excluding Sutton, Bass and Tamayo studies individually 
made no significant difference. The removal of all 3 together causes 
meta-analysis to lose statistical significance.
Outcome 2: excluding Bass, Park, Koranyi; no significant change
Outcome 3: excluding Park; no significant change
Outcome 4: excluding Arata 1989a; no significant change
Outcome 5: excluding Pruksachat.; no significant change
Outcome 6: excluding Arata 1989b; only trial providing data to this 
outcome, so no data now available.
Outcomes 7 & 8: Moraes-Barbosa 1986 is the only trial providing data 
for both outcomes, so no data now available.
Adherence to 
treatment in patients 
with high blood 
pressure [12]
38 1. Gabriel (1977) [35]
2. Hamilton (1993) [36]
3. Kerr (1985) [37]
4. Morisky (1985) [38]
5. Rehder (1980) [39]
58 different interventions were tested on 15519 patients. Review did 
not do meta-analysis due to heterogeneity between studies in terms of 
interventions and the methods used to measure adherence. Missing 
trials were all small studies of poor methodological quality. Their 
exclusion would have little impact on the final conclusions.
Preventing infection 
in nephrotic 
syndrome [14]
5 1. Dou (2000) [40]
2. Li (2000) [41]
3. Zhang (2000) [42]
4. Tong (1998) [43]
The 4 missing trials were included in 3 of 4 of the meta-analyses.
Outcome 1: Excluding Dou and Tong; no significant change.
Outcome 2: Tong was the only trial providing data, so no data now 
available.
Outcome 3: Zhang was the only trial providing data, so no data now 
available.
Outcome 4: Li was the only trial providing data, so no data now 
available.
Probiotics for 
treating infectious 
diarrhoea [17]
25 Sugita (1994) [44] Sugita included in 7 of 27 meta-analyses in review. Exclusion of Sugita 
makes no significant difference to any of the clinical outcomes. The only 
outcome to lose statistical significance is not a clinical outcome, but a 
sensitivity analysis based on a methodological characteristic (blinding).
Psychological 
interventions for 
coronary heart 
disease [16]
56 1.Gallacher (1997) [45]
2. Mitsibounas (1992) [46]
1. Gallacher was included in 8 of 28 meta-analyses. In six, omission 
makes no difference.
In 2, confidence intervals are much wider; in the one of these statistical 
significance is lost. 2. Mitsibounas was included in 5 of 28 meta-analyses. 
Excluding Mitsibounas makes no significant difference in four outcomes. 
In the other, it cause causes the meta-analysis to lose statistical 
significance
Insulin analogues 
versus human insulin 
[47]
43 Iwamoto (2001) [48] Iwamoto in 4 of the 8 meta-analyses. Exclusion of Iwamoto makes no 
significant difference to any of the outcomes.
Tramadol for 
neuropathic pain [49]
5 Leppert (2001) [50] Leppert not used in either of 2 meta-analyses in the review. The review 
says: 'Given the small (even if unknown) number of subjects and the 
non-blinded nature of the trial it is probably not possible to draw and 
conclusions about their relative efficacy from this study.BMC Medical Research Methodology 2005, 5:23 http://www.biomedcentral.com/1471-2288/5/23
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RCTs by authors should mean that all RCTs are indexed
with the appropriate publication type in MEDLINE, and
also result in more sensitive retrieval of RCTs using the
BRSS.
The BRSS had a sensitivity of 96% for RCTs in journal arti-
cles. Compared to the HSSS, the BRSS reduced the
MEDLINE retrieval by 84%. This would represent a major
time and cost saving in manual screening.
The strengths of this study include firstly that we used
Cochrane reviews, as they approximate the 'gold standard'
in searching, due to the requirement for exhaustive
searches. Hence we can be fairly certain that we were start-
ing with as comprehensive set of included trials as possi-
ble. Secondly, we quantified the impact of omitting trials
not found with the simplified search.
A weakness of this study was that we could not check
whether the RCTs would have been in CENTRAL at the
time the searchers did their searching, and hence elimi-
nate the possibility that some RCTs were first identified by
the reviewers, and then passed to CENTRAL. However,
given the extensive searching routinely done for CEN-
TRAL, it is highly likely most RCTs would be identified
sooner or later, and therefore be included in a subsequent
update of the review.
A range of subject areas was included, which helps with
generalisability, though it may decrease power in any one
subject area. However, a recent study on identifying qual-
ity RCTs in pain relief gives general support to our find-
ings [18]. It investigated the efficiency of the search
strategy DBRCT.af., ("double-blind," "random," or varia-
tions of these terms) in MEDLINE and EMBASE, and was
found have a sensitivity of 97%.
Change in the proportion of RCTs with 'random$' in the title or abstract (with three year moving average trendline added) Figure 1
Change in the proportion of RCTs with 'random$' in the title or abstract (with three year moving average trendline added).
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This study focused only on a simplified search strategy for
retrieving RCTs in journal articles, since these made up the
vast majority of the references used in Cochrane reviews,
and are most important in terms of the quality and quan-
tity of assessable data available. By contrast, most grey lit-
erature (the vast majority of which is meeting abstracts)
gives very limited data. However, CENTRAL includes
many grey literature trials, so these will be identified with
the BRSS.
There are currently over 2200 Cochrane reviews, and these
will need maintaining in the future. Authors may be
encouraged to update their reviews, if they can be
confident they can identify RCTs comprehensively with a
simple search. The simplified search may also be useful
for those doing reviews in a tight timescale, or by clini-
cians who just want a rapid but reliable answer to a ques-
tion. There is a case for the 'not quite perfect but rapid,
easy and almost complete' search'.
In practice, some of the few trials missed by the BRSS were
small or of poor quality, and as Egger and colleagues have
reported, the last few studies found by exhaustive search-
ing could introduce bias, by being of poor quality [19].
The issue is whether the marginal benefits of exhaustive
searching justify the extra costs. When the inclusion crite-
ria demand only RCTS, this study suggests that exhaustive
searching is now, in the era of CENTRAL and CONSORT,
no longer cost-effective.
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